Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free CYCN Stock Alerts

Cyclerion Therapeutics (CYCN) Competitors

Cyclerion Therapeutics logo
$3.15 -0.11 (-3.37%)
Closing price 04:00 PM Eastern
Extended Trading
$3.05 -0.10 (-3.17%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CYCN vs. GRML, TELO, IXHL, RLYB, and ATOS

Should you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Greenland Mines Ltd. Common Stock (GRML), Telomir Pharmaceuticals (TELO), Incannex Healthcare (IXHL), Rallybio (RLYB), and Atossa Genetics (ATOS). These companies are all part of the "pharmaceutical products" industry.

How does Cyclerion Therapeutics compare to Greenland Mines Ltd. Common Stock?

Cyclerion Therapeutics (NASDAQ:CYCN) and Greenland Mines Ltd. Common Stock (NASDAQ:GRML) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Greenland Mines Ltd. Common Stock has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -39.23% beat Greenland Mines Ltd. Common Stock's return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclerion Therapeutics-170.11% -39.23% -35.62%
Greenland Mines Ltd. Common Stock N/A -137.58%-126.00%

Cyclerion Therapeutics has higher revenue and earnings than Greenland Mines Ltd. Common Stock. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Greenland Mines Ltd. Common Stock, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclerion Therapeutics$2.07M6.59-$3.53M-$1.16N/A
Greenland Mines Ltd. Common StockN/AN/A-$10.55M-$0.32N/A

75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 20.1% of Greenland Mines Ltd. Common Stock shares are held by institutional investors. 34.3% of Cyclerion Therapeutics shares are held by insiders. Comparatively, 9.9% of Greenland Mines Ltd. Common Stock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cyclerion Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Greenland Mines Ltd. Common Stock has a beta of 7.61, suggesting that its share price is 661% more volatile than the S&P 500.

In the previous week, Greenland Mines Ltd. Common Stock had 2 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 3 mentions for Greenland Mines Ltd. Common Stock and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 0.00 beat Greenland Mines Ltd. Common Stock's score of 0.00 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cyclerion Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Greenland Mines Ltd. Common Stock
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Greenland Mines Ltd. Common Stock
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Cyclerion Therapeutics beats Greenland Mines Ltd. Common Stock on 7 of the 12 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

In the previous week, Telomir Pharmaceuticals and Telomir Pharmaceuticals both had 1 articles in the media. Telomir Pharmaceuticals' average media sentiment score of 0.00 equaled Cyclerion Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Telomir Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cyclerion Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Telomir Pharmaceuticals has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -39.23% beat Telomir Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Telomir PharmaceuticalsN/A -315.26% -259.29%
Cyclerion Therapeutics -170.11%-39.23%-35.62%

Telomir Pharmaceuticals has a beta of -0.21, suggesting that its share price is 121% less volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

Cyclerion Therapeutics has higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Cyclerion Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.33N/A
Cyclerion Therapeutics$2.07M6.59-$3.53M-$1.16N/A

Summary

Cyclerion Therapeutics beats Telomir Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Cyclerion Therapeutics has higher revenue and earnings than Incannex Healthcare. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incannex Healthcare$90K629.64-$46.88M-$8.41N/A
Cyclerion Therapeutics$2.07M6.59-$3.53M-$1.16N/A

In the previous week, Cyclerion Therapeutics had 1 more articles in the media than Incannex Healthcare. MarketBeat recorded 1 mentions for Cyclerion Therapeutics and 0 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.00 equaled Cyclerion Therapeutics'average media sentiment score.

Company Overall Sentiment
Incannex Healthcare Neutral
Cyclerion Therapeutics Neutral

Incannex Healthcare has a beta of 7.22, suggesting that its share price is 622% more volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Incannex Healthcare has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -39.23% beat Incannex Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Incannex HealthcareN/A -114.95% -103.38%
Cyclerion Therapeutics -170.11%-39.23%-35.62%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incannex Healthcare
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Cyclerion Therapeutics beats Incannex Healthcare on 8 of the 12 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Rallybio?

Cyclerion Therapeutics (NASDAQ:CYCN) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

Cyclerion Therapeutics has a net margin of -170.11% compared to Rallybio's net margin of -1,046.39%. Cyclerion Therapeutics' return on equity of -39.23% beat Rallybio's return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclerion Therapeutics-170.11% -39.23% -35.62%
Rallybio -1,046.39%-56.93%-52.67%

Cyclerion Therapeutics has higher revenue and earnings than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than Cyclerion Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclerion Therapeutics$2.07M6.59-$3.53M-$1.16N/A
Rallybio$860K87.84-$8.98M-$2.56N/A

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by insiders. Comparatively, 10.3% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Rallybio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Rallybio had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Rallybio and 1 mentions for Cyclerion Therapeutics. Rallybio's average media sentiment score of 1.05 beat Cyclerion Therapeutics' score of 0.00 indicating that Rallybio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cyclerion Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rallybio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cyclerion Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.1, meaning that its stock price is 210% less volatile than the S&P 500.

Summary

Cyclerion Therapeutics beats Rallybio on 9 of the 13 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Atossa Genetics?

Cyclerion Therapeutics (NASDAQ:CYCN) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

Atossa Genetics has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -39.23% beat Atossa Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclerion Therapeutics-170.11% -39.23% -35.62%
Atossa Genetics N/A -65.56%-57.74%

Cyclerion Therapeutics has higher revenue and earnings than Atossa Genetics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclerion Therapeutics$2.07M6.59-$3.53M-$1.16N/A
Atossa GeneticsN/AN/A-$34.77M-$3.60N/A

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Atossa Genetics has a consensus target price of $36.33, suggesting a potential upside of 551.14%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Cyclerion Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Atossa Genetics
2 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.40

In the previous week, Atossa Genetics had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Atossa Genetics and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 0.00 equaled Atossa Genetics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cyclerion Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Atossa Genetics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cyclerion Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.

Summary

Cyclerion Therapeutics beats Atossa Genetics on 8 of the 15 factors compared between the two stocks.

Get Cyclerion Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYCN vs. The Competition

Export
MetricCyclerion TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$14.12M$3.40B$6.25B$11.77B
Dividend YieldN/A2.23%2.74%5.26%
P/E Ratio-2.7238.5729.2527.07
Price / Sales6.59280.02504.6873.47
Price / CashN/A125.0643.3053.90
Price / Book1.367.059.676.69
Net Income-$3.53M$23.62M$3.55B$332.64M
7 Day Performance3.62%3.67%1.70%2.01%
1 Month Performance-48.78%7.17%5.62%9.19%
1 Year Performance6.06%67.04%34.42%39.59%

Cyclerion Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYCN
Cyclerion Therapeutics
0.1186 of 5 stars		$3.15
-3.4%		N/AN/A$14.12M$2.07MN/A30
GRML
Greenland Mines Ltd. Common Stock
0.0999 of 5 stars		$0.43
-4.7%		N/AN/A$52.13MN/AN/A5
TELO
Telomir Pharmaceuticals
N/A$1.44
-1.0%		N/AN/A$49.34MN/AN/A1
IXHL
Incannex Healthcare
0.1782 of 5 stars		$4.13
+1.1%		N/AN/A$49.21M$90KN/A3
RLYB
Rallybio
0.3755 of 5 stars		$8.81
+0.1%		N/AN/A$46.58M$860KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CYCN) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel